

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence

Radhika Mathur^o, Yalan Zhang, Matthew R. Grimmer, Chibo Hong, Michael Zhang, Saumya Bollam, Kevin Petrecca, Jennifer Clarke, Mitchel S. Berger, Joanna J. Phillips, Nancy Ann Oberheim-Bush, Annette M. Molinaro, Susan M. Chang, and Joseph F. Costello^o

Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA (R.M., Y.Z., M.R.G., C.H., M.Z., S.B., J.C., M.S.B., J.J.P., N.A.O-B., A.M.M., S.M.C., J.F.C.); Bioinformatics and Computational Biology, Discovery Oncology, Genentech, San Francisco, California, USA (M.R.G.); Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada (K.P.)

Corresponding Author: Joseph F. Costello, Helen Diller Family Cancer Research Building HD471, 1450 3rd Street, San Francisco, CA 94158 (joseph.costello@ucsf.edu)

Abstract

Background. Emerging data suggest that a subset of patients with diffuse isocitrate dehydrogenase (IDH)-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors. It is currently unclear why some TMZ-treated LGG patients recur with hypermutation while others do not. *MGMT* encodes O6-methylguanine-DNA methyltransferase, a DNA repair protein that removes cytotoxic and potentially mutagenic lesions induced by TMZ. Here, we hypothesize that epigenetic silencing of *MGMT* by promoter methylation facilitates TMZ-induced mutagenesis in LGG patients and contributes to development of hypermutation at recurrence.

Methods. We utilize a quantitative deep sequencing assay to characterize *MGMT* promoter methylation in 109 surgical tissue specimens from initial tumors and post-treatment recurrences of 37 TMZ-treated LGG patients. We utilize methylation arrays to validate our sequencing assay, RNA sequencing to assess the relationship between methylation and gene expression, and exome sequencing to determine hypermutation status.

Results. Methylation level at the *MGMT* promoter is significantly higher in initial tumors of patients that develop hypermutation at recurrence relative to initial tumors of patients that do not (45.7% vs 34.8%, $P = 0.027$). Methylation level in initial tumors can predict hypermutation at recurrence in univariate models and multivariate models that incorporate patient age and molecular subtype.

Conclusions. These findings reveal a mechanistic basis for observed differences in patient susceptibility to TMZ-driven hypermutation. Furthermore, they establish *MGMT* promoter methylation level as a potential biomarker to inform clinical management of LGG patients, including monitoring and treatment decisions, by predicting risk of hypermutation at recurrence.

Key Points

1. *MGMT* promoter methylation facilitates TMZ-induced mutagenesis and contributes to hypermutation.
2. *MGMT* promoter methylation level in newly diagnosed LGG predicts hypermutation at recurrence.
3. *MGMT* promoter methylation may serve as a biomarker to inform clinical decision making in LGG.

Importance of the Study

Optimal clinical management remains controversial for patients diagnosed with diffuse IDH-mutant LGG as tumors inevitably recur following surgical resection and eventually cause death. While the chemotherapeutic agent TMZ extends survival in patients with glioblastoma, its clinical benefits in LGG are less clear and must be weighed against potential treatment-related risks. TMZ is potently mutagenic and drives hypermutation in association with malignant progression in a subset of patients with an initial diagnosis of LGG. Here, we

identify promoter methylation at *MGMT* in initial LGG tumors as a predictor of hypermutation at recurrence. Our findings reveal a mechanistic basis for observed differences in susceptibility of LGG patients to TMZ-driven hypermutation. As optimal clinical management of LGG continues to be defined, our findings establish *MGMT* promoter methylation at diagnosis as a potential biomarker to inform monitoring and treatment decisions by stratifying patients based upon risk of developing hypermutation at recurrence.

Diffuse isocitrate dehydrogenase (IDH)-mutant low-grade gliomas (LGGs) are slow-growing brain tumors that include astrocytomas and oligodendrogliomas. Both LGG subtypes are characterized at the molecular level by mutations in *IDH1/2*, with astrocytomas showing additional mutations in *ATRX* and *TP53*, and oligodendrogliomas showing combined whole-arm losses of chromosome 1p and 19q.¹⁻³ The infiltrative nature of LGGs precludes complete surgical resection and these tumors inevitably recur, albeit at highly variable intervals. Standard of care treatment of LGG is controversial, with post-surgical treatment regimens ranging from observation to aggressive treatment with radiotherapy in combination with chemotherapy.⁴ Temozolomide (TMZ) is an oral chemotherapeutic agent with pharmacological properties that enable crossing of the blood-brain barrier. Although it is commonly administered to LGG patients as adjuvant therapy following surgery, its clinical benefits remain unclear.^{5,6} For example, there was no significant difference in progression-free survival in a phase III study of LGG patients treated with either TMZ alone or radiotherapy alone.⁷ In another phase II study of LGG patients treated with adjuvant TMZ, only 6% of patients showed a partial radiographic response and none showed a complete response.⁸

LGGs arise in young, otherwise healthy patients with good prognosis relative to glioblastoma (GBM), a high-grade brain tumor that is rapidly fatal if left untreated. The potential benefits of treatment for LGG patients must therefore be carefully weighed against potential treatment-related risks. Like many chemotherapeutic agents, TMZ is potently mutagenic.^{9,10} TMZ alkylates the O⁶ position of guanine which, during DNA replication, mispairs with thymine instead of cytosine and results in G:C > A:T transition mutations. In a pilot study of TMZ-treated patients with an initial diagnosis of astrocytic LGG, we identified a hypermutator phenotype in 6 out of 10 recurrences.¹¹ These recurrences harbored an order of magnitude of more mutations than non-hypermutated recurrences, nearly all showing the TMZ-mutagenesis signature of G:C > A:T transitions occurring predominantly at CpC and CpT dinucleotides. Importantly, all hypermutated recurrences harbored TMZ-induced mutations in glioma driver genes and underwent malignant progression to GBM. However, it has been unclear from this study and others why some patients develop hypermutation following TMZ treatment while others do not.

Understanding the risk of developing TMZ-driven hypermutation may inform clinical decision making regarding monitoring and treatment decisions for patients diagnosed with LGG. O⁶-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that counters the cytotoxic and mutagenic activity of TMZ by removing alkyl groups from the O⁶ position of the guanine.^{12,13} As MGMT is irreversibly inactivated following removal of a single alkyl group, the amount of MGMT protein in a cell is a limiting factor in the repair of TMZ-induced lesions. In previous studies of recurrences from TMZ-treated LGGs, we have observed elevated levels of *MGMT* promoter methylation in hypermutated recurrences relative to non-hypermutated recurrences.^{11,14} Other groups have also observed co-occurrence of *MGMT* promoter methylation and hypermutation in recurrent tumors from LGG and GBM patients who received TMZ.¹⁵⁻¹⁷ Based on these observations, we hypothesize that epigenetic silencing of *MGMT* by promoter methylation facilitates TMZ-induced mutagenesis and contributes to the development of hypermutation. Here, we conduct a longitudinal cohort study of LGG patients who received adjuvant TMZ with the aim to determine whether *MGMT* promoter methylation level in initial tumors is a predictor of hypermutation at recurrence.

Materials and Methods

Sample Acquisition

All initial and recurrent tumor samples were collected during surgical resection and were either snap frozen and stored in liquid nitrogen, or formalin fixed and paraffin embedded (FFPE). In cases where more than one sample from a tumor was investigated, those samples were independent, spatially distinct pieces. DNA was extracted and processed by a standard phenol chloroform extraction as previously described¹¹ or with the Qiagen FFPE DNA extraction kit (Qiagen) following manufacturer instructions. Samples were obtained from the Neurosurgery Tissue Bank at the University of California San Francisco (UCSF). Additional samples were obtained from The Brain Tumour Research Centre at McGill University. Sample use was approved by the Committee on Human Research at UCSF, and

research was approved by the institutional review board at UCSF. All patients provided informed written consent.

Evaluation of Hypermutation Status

Exome-sequencing of the initial tumor and matched recurrence, along with germline (blood) DNA was conducted using either Agilent (SureSelect Human All Exon 50MB, SureSelect Human All Exon v4) or NimbleGen (SeqCap EZ Exome v3) exome capture kits according to manufacturer's protocol. Exome-sequencing data has been previously published for 11 patients^{11,14,18,19} and is newly generated for 26 patients (Supplementary Table 1). Paired-end sequencing data from exome capture libraries were aligned to the reference human genome (hg19) and mutations were called as previously described.¹¹ The software package deconstructSigs²⁰ was used to conduct mutational signature analysis yielding proportionate contributions of each signature to individual exomes. Signature numbers correspond to those previously described.²¹ TMZ-induced hypermutation was defined by >40% contribution from mutational signature 11, which is associated with TMZ treatment.

Quantitative Sequencing–Based Assay of MGMT Promoter Methylation Level

Bisulfite amplicon sequencing (BSAS), a method that couples bisulfite conversion of genomic DNA with PCR enrichment of targeted regions and next-generation sequencing, was conducted as previously described²² using 250 ng–1 µg of genomic DNA isolated from fresh frozen or FFPE tissues. Quality control and quantification of BSAS methylation levels were conducted utilizing the Bismark software package.²³ For validation, genome-scale methylation datasets were utilized from Infinium 450K or 850K (EPIC) Beadchip Arrays.²⁴ These datasets have been previously published for 10 patients^{18,19} and are newly generated for 19 patients (Supplementary Table 1). Methylation at cg12981137 in the *MGMT* promoter region was calculated from Infinium array datasets using the MGMT-STP27 software package.^{25,26}

Quantification of MGMT Gene Expression

RNA was isolated from tumor tissue samples with Trizol (Invitrogen) according to manufacturer's instructions. Transcriptome sequencing libraries were prepared as previously described.¹¹ Transcriptomes have previously been published for 6 patients^{18,19} and are newly generated for 12 patients (Supplementary Table 1). Read summarization was performed with featureCounts.²⁷ Features with low read counts (row sums <1) were removed and the remainder were Variance-Stabilizing Transformed (VST) normalized with DESeq2.²⁸ Batch correction was performed with ComBat.²⁹ Transcripts assigned to ENSG00000170430.9 were considered as quantitation of *MGMT* gene expression.

Logistic Regressions and Predictive Modeling

Univariate and multivariate logistic regression models were used to assess the associations of clinical and methylation

variables with hypermutation status. In addition, recursive partitioning via the partDSA algorithm,³⁰ was employed to assess associations and explore cutoffs of continuous covariates. Models were evaluated via likelihood ratio tests and misclassification prediction error rates.

Results

Patient Cohort and Course After TMZ Treatment

Patient inclusion in this cohort was dependent upon (i) an initial diagnosis of grade II LGG, (ii) adjuvant TMZ treatment, and (iii) availability of at least one tissue sample each from the initial untreated tumor and a posttreatment recurrence. Histological grading was performed by a clinical neuropathologist, across multiple samples when available, and classification incorporated molecular genetic features as described in the 2016 World Health Organization guidelines.² Out of the 37 patients included in the study, 23 had an initial diagnosis of grade II astrocytoma and 14 had an initial diagnosis of grade II oligodendroglioma (Table 1). Of the astrocytomas, 6 (26.1%) maintained grade II features while 6 (26.1%) progressed to grade III anaplastic astrocytoma and 11 (47.8%) to grade IV GBM. Of the oligodendrogliomas, 3 (21.4%) maintained grade II features while the remaining 11 (78.6%) underwent malignant progression to grade III anaplastic oligodendroglioma.

Hypermutation Status at Recurrence

In order to determine whether recurrent tumor samples had undergone hypermutation, we utilized new and previously reported^{11,14,18,19} whole-exome sequencing data to characterize the mutational burden of all tissue samples from recurrent tumors. We then conducted mutational signature analysis to specifically detect the presence of G:C > A:T transitions consistent with TMZ-induced damage.²¹ Hypermutated recurrence samples harbored a median of 2120 mutations (range, 411–3980) in the exome, while non-hypermutated recurrence samples harbored a median of 59 mutations (range, 20–138) (Supplementary Table 2). All recurrence samples analyzed were hypermutated for 15 patients (HM, 40.5%), while no recurrence samples analyzed were hypermutated for 19 patients (nonHM, 51.4%). The remaining 3 patients showed hypermutation in some recurrence samples, but not others (Mixed HM status, 8.1%). This is consistent with intratumoral heterogeneity, which is a key feature of glioma that reflects evolutionary dynamics of cancer.^{31,32} TMZ-induced hypermutation likely occurs only in few cells, which then undergo clonal expansion. If initial surgical resection is incomplete, for example, residual tumor may continue to grow and be resampled at recurrence as a non-hypermutated component of tumor.

Patients that underwent hypermutation at recurrence generally progressed to higher-grade tumors: 14/15 (93.3%) HM patients progressed to grade III or IV tumors, while only 12/19 (63.2%) nonHM patients progressed ($P = 0.039$ by chi-square test; Fig. 1A). Clinical follow-up of the only HM patient in our cohort with a grade II recurrence (patient 337) reveals that the patient progressed within

2 years of the first recurrence to a second recurrence with grade III features. We sought to determine whether differences in hypermutation status at recurrence could be explained by known patient or treatment-related factors. We found no association between HM status and patient age at diagnosis (Fig. 1B) or number of TMZ cycles received (Fig. 1C). While patients received a median of 12 cycles

of adjuvant TMZ treatment, one nonHM patient (patient 163) received an outlier 51 cycles of TMZ treatment over the span of 5 years. This patient had one posttreatment recurrence, which was not hypermutated and had maintained grade II features. Collectively, these data suggest that these otherwise important prognostic factors are not predictive of risk for developing hypermutation.

Table 1. Description of patient cohort

	Astrocytoma (n = 23)	Oligodendroglioma (n = 14)	Overall (n = 37)
Age at diagnosis			
Median [interquartile range (IQR)]	31.0 [27.5, 38.5]	37.0 [32.25, 44]	33.0 [28.0, 39.0]
Sex			
Female	11 (47.8%)	6 (42.9%)	17 (45.9%)
Male	12 (52.2%)	8 (57.1%)	20 (54.1%)
TMZ cycles			
Median [IQR]	12.0 [11.75, 15.25]	21.5 [12.0, 24.0]	12.0 [12, 22.5]
Grade at recurrence			
II	6 (26.1%)	3 (21.4%)	9 (24.3%)
III	6 (26.1%)	11 (78.6%)	17 (45.9%)
IV	11 (47.8%)		11 (29.7%)
HM status at recurrence			
HM	9 (39.1%)	6 (42.9%)	15 (40.5%)
Mixed	2 (8.7%)	1 (7.1%)	3 (8.1%)
nonHM	12 (52.2%)	7 (50.0%)	19 (51.4%)




Fig. 1 Patient hypermutation status and association with clinical characteristics. (A) Hypermutation (HM) status by grade at recurrence. (B) HM status by patient age at diagnosis. (C) HM status by number of TMZ cycles received prior to recurrence.

Assaying Methylation at the MGMT Promoter

To test our hypothesis of a role for *MGMT* promoter methylation in the development of TMZ-driven hypermutation, we characterized methylation levels in the *MGMT* promoter region in a quantitative and high-throughput manner using BSAS.²² We targeted a 273 bp region of interest (chr10: 129467210–129467482; hg38) containing 27 cytosine-phosphate-guanine (CpG) sites. This region spans that interrogated by our previous study¹⁴ and that which is commonly interrogated by methylation-specific PCR (MSP), a clinically used method that provides a binary indicator of methylation status.³³ Notably, the region encompasses an enhancer located at the first exon/intron boundary³⁴ as well as regions at which methylation at CpG sites is linked to silencing of *MGMT* gene expression.^{35–37} Sequence motif-analysis³⁸ and examination of ENCODE ChIP-Seq binding profiles³⁹ indicate that the region is likely bound and acted upon by several transcriptional regulators (Supplementary Figure 1).

We characterized methylation by BSAS at an average of 28635x coverage on 109 total initial tumor and recurrence samples from all 37 patients in the cohort (Supplementary Table 4). We utilized new and previously reported^{18,19} data from Infinium arrays²⁴ to perform independent validation of BSAS results on 75 of the tumor samples. Infinium arrays include two CpG sites in the *MGMT* promoter region that are linked to MSP-determined *MGMT* methylation status and *MGMT* gene expression.^{25,26} One of these CpG sites (cg12981137, located +174 bp from the transcription start site [TSS]) is within the region assayed by BSAS. Comparison of methylation measures at this particular

CpG site from both methods revealed a high degree of concordance across samples (Fig. 2A).

As methylation of the *MGMT* promoter is associated with gene silencing, we sought to directly investigate the relationship between methylation in the region assayed by BSAS and *MGMT* gene expression. We utilized new and previously reported^{18,19} data from whole transcriptome profiling on 41 samples from initial tumors and recurrences. We examined correlations between methylation levels at each of the 27 CpG sites in the region and *MGMT* mRNA level. Adjusting for multiple-hypothesis testing by the Holm–Bonferroni method, 3 CpG sites (+106, +113, +142 bp from TSS) showed strong, inverse relationships between methylation levels and gene expression that were statistically significant (Fig. 2B). All 3 CpG sites were within regions where methylation has been previously linked to *MGMT* gene expression: “hotspot,”³⁵ “concordant region,”³⁶ and “differentially methylated region” (DMR).³⁷

MGMT Promoter Methylation Level at Recurrence Is Associated with Hypermutation Status

To investigate the relationship between *MGMT* promoter methylation and hypermutation, we began by characterizing methylation profiles of individual recurrent tumor samples in which we had detected the presence or absence of hypermutation. We conducted hierarchical clustering of *MGMT* methylation profiles using Ward’s minimum variance method, finding that hypermutated recurrence samples generally showed increased methylation levels across CpG sites and clustered separately from those that were




Fig. 2 Validation of bisulfite amplicon sequencing (BSAS) method for assaying *MGMT* promoter methylation level. (A) Association between methylation level at CpG site +174 bp from TSS assayed by BSAS and by Infinium Array across samples. (B) Association between methylation level at each CpG site assayed by BSAS and *MGMT* mRNA level across samples. Pearson correlations and *P*-values adjusted for multiple hypothesis testing are shown for each CpG site labeled by distance from TSS. Sequence annotations are shown for regions assayed by methylation-specific PCR (MSP), an enhancer, and regions for which associations between methylation and transcription have previously been shown (hotspot, DMR, concordant region).

not hypermuted (Fig. 3A). A similar separation of clusters was observed when this analysis was restricted to only the 3 CpG sites that showed a significant inverse relationship with *MGMT* gene expression (+106, +113, +142 bp from TSS; Supplementary Figure 2). Levels of *MGMT* gene expression were significantly reduced in hypermuted recurrences relative to non-hypermuted recurrences (Fig. 3B). A negative relationship was observed between average *MGMT* promoter methylation level and *MGMT* gene expression level (Pearson $R = -0.59$, $P = 0.002$), indicating that *MGMT* was epigenetically silenced in hypermuted recurrences by promoter methylation (Fig. 3C).

While individual recurrence samples from HM and nonHM patients showed similar levels of methylation at the *MGMT* promoter, samples from patients with Mixed HM status showed greater variability (Fig. 4A). We used a bootstrapping-based methodology to quantify this, randomly taking one sample from each patient, and then resampling 100 times to generate a distribution of methylation levels. We found a wider variance of methylation levels for samples from patients with Mixed HM status (mean 37.3, SD 8.600) relative to patients that were HM (mean 45.7, SD 0.973) or nonHM (mean 20.5, SD 0.387) (Fig. 4B). We next examined individual recurrence samples for each of the 3 patients with Mixed HM status. For each patient, we found that samples from the same tumor that were hypermuted showed higher methylation levels at the *MGMT* promoter than samples that were not hypermuted (Fig. 4C). Thus, a link between

MGMT promoter methylation level and hypermutation is supported not only by interpatient analysis of recurrent tumors, but also by intratumoral analysis of individual samples from recurrent tumors.

MGMT Promoter Methylation Level in Initial Tumors Predicts Hypermutation at Recurrence

We next sought to determine whether *MGMT* promoter methylation levels in initial, untreated tumors differed between patients who developed hypermutation at recurrence and patients who did not. We found higher methylation at nearly every CpG site in the region evaluated in initial tumors from HM patients than those from nonHM patients (Fig. 5A). Average methylation level was significantly higher in initial tumors of HM patients than nonHM patients (46.0% vs 34.8%, $P = 0.027$ by Wilcoxon rank-sum test, Fig. 5B). Average methylation level was also significantly higher in recurrence tumors of HM patients than nonHM patients (44.0% vs 20.5%, $P < 0.001$ by Wilcoxon rank-sum test), confirming observations from our previous study.¹⁴ For HM patients, methylation levels did not significantly change between initial tumors and recurrences (46.0% vs 45.6%, $P = 0.86$ by Wilcoxon signed-rank test; Fig. 5C). In contrast, for nonHM patients, methylation levels significantly decreased between initial tumors and recurrences (34.8% vs 20.5%, $P < 0.001$ by Wilcoxon signed-rank test; see also Fig. 5D).




Fig. 3 Hypermutation in individual recurrence samples is associated with increased *MGMT* promoter methylation and reduced expression. (A) Hierarchical clustering by Ward's minimum variance method of methylation levels at 27 CpG sites for individual recurrence samples labeled by patient ID number, presence or absence of hypermutation (HM), and subtype (A: astrocytoma, O: oligodendroglioma). (B) *MGMT* expression level by RNA log count for individual recurrence samples by presence or absence of hypermutation. (C) *MGMT* expression level by RNA log count and average methylation level at the *MGMT* promoter for each individual recurrence sample.




Fig. 4 Intratumoral analysis of *MGMT* promoter methylation and hypermutation. (A) Average methylation level at the *MGMT* promoter methylation for individual recurrence samples from the patient, classified by HM status. (B) Quantification of variation in *MGMT* promoter methylation levels by bootstrapping. (C) Average methylation level and presence of hypermutation in individual recurrence samples of patients with Mixed HM status.

Given differences in *MGMT* promoter methylation level between initial tumors of patients that did and did not develop hypermutation, we evaluated logistic regression models to test the association of methylation levels in initial tumors with hypermutation status at recurrence. To enable binary classification of hypermutation status, we followed precedent from neuropathology practice where the most malignant component of the tumor defines clinical grade, even if remnants of low-grade tumor are present alongside transformation. We therefore classified any patient with at least one hypermutated recurrence sample as hypermutated. A univariate logistic model revealed that average methylation level in initial tumors was associated with hypermutation at recurrence (odds ratio, 1.06; 95% CI [1.01, 1.12], $P = 0.04$). Average methylation level remained significant after adjusting for molecular subtype (astrocytoma vs oligodendroglioma)

and age of diagnosis (odds ratio, 1.09; 95% CI [1.02, 1.18], $P = 0.02$). We tested other clinical variables including sex and number of TMZ cycles received in univariate and multivariate models, but did not find significant associations with hypermutation at recurrence. Evaluation of individual CpG sites revealed that methylation at the CpG site +113 bp from TSS in the initial tumor was most associated with hypermutation at recurrence (odds ratio, 1.04; 95% CI [1.01, 1.08], $P = 0.01$). Notably, this site has been associated with silencing of *MGMT* gene expression by this study and others.^{35–37} Finally, we conducted regression tree analyses,³⁰ which identified average methylation level in an initial tumor as a significant predictor of hypermutation at recurrence. An average methylation level of greater than 42.5% was associated with hypermutation ($P < 0.01$ by Fisher's exact test) (Fig. 5E, Supplementary Table 5).




Fig. 5 *MGMT* promoter methylation level in initial tumors predicts hypermutation status at recurrence. (A) Methylation level at each CpG site for initial tumors and recurrences of patients by HM status. (B) Average methylation level for initial tumors and recurrences of patients by HM status. (C) Paired analysis of average methylation level between initial tumors and recurrences. (D) Change in average *MGMT* promoter methylation level from initial tumor to recurrence. (E) Regression tree identifying average methylation level in initial tumors as a significant predictor of HM status at recurrence.

Discussion

This study establishes *MGMT* promoter methylation level in initial untreated LGG tumors as a significant predictor of TMZ-driven hypermutation at recurrence. This study also confirms our previous observation¹⁴ that *MGMT* promoter methylation levels at recurrence are higher in patients who develop hypermutation than in patients who do not. Collectively, these results provide evidence in support of our hypothesis that epigenetic silencing of *MGMT* by promoter methylation facilitates TMZ-induced mutagenesis and contributes to the development of hypermutation. They reveal a mechanistic basis for observed differences

in propensity of TMZ-treated patients with LGG to develop hypermutation at recurrence. Furthermore, they establish the potential of *MGMT* promoter methylation to serve as a clinically useful biomarker for LGG patients by predicting risk of developing TMZ-driven hypermutation at recurrence.

MGMT promoter methylation is associated with chemosensitivity and is prognostic for longer overall survival in GBM patients and in patients with astrocytic LGG that are classified as “high-risk” due to patient age, tumor size and invasion into corpus callosum, and/or preoperative neurological deficits.^{40,41} In longitudinal studies that have been conducted of TMZ-treated GBM patients, recurrences show downward shifts in levels of *MGMT* promoter

methylation consistent with increased TMZ resistance in less methylated clones.^{42–45} In our study of LGG patients, we find that patients who do not develop hypermutation at recurrence also show a downward shift in *MGMT* promoter methylation level. However, patients that develop hypermutation show increased *MGMT* promoter methylation levels in initial tumors that are maintained at recurrence. Taken together, the data support a model whereby *MGMT* promoter methylation in LGG patients confers sensitivity both to TMZ-induced cytotoxicity and to TMZ-induced mutagenesis, which is prerequisite to the generation and selection of hypermutated tumor clones. *MGMT* promoter methylation level in initial tumors may thus be used to anticipate future aggressive clonal outgrowths of hypermutated and malignantly transformed tumor cells.

Standard of care for LGG patients remains controversial, with post-surgical treatment regimens ranging from observation to aggressive treatment with radiotherapy in combination with chemotherapy.⁴ Knowledge of *MGMT* promoter methylation level may provide insight into risk for developing TMZ-driven hypermutation leading to appropriate patient counseling. For example, the aforementioned patient (patient 163) who received 51 cycles of TMZ treatment had a low average *MGMT* promoter methylation level of 28.3% in the initial tumor and may have been predicted to be of low risk for developing hypermutation. Patients with higher levels of *MGMT* promoter methylation may be considered candidates for alternative treatments such as IDH inhibitors currently in development.^{46,47} If treated with TMZ, these patients may be monitored more closely by imaging surveillance. Notably, while hypermutation may contribute to malignancy, the radically altered genome of hypermutated tumors may also present new opportunities for therapeutic exploitation.^{6,48} For example, the mutational burden and clonal mutational architecture of hypermutated tumors may increase neoantigen load, thereby conferring sensitivity to immunotherapy. Hypermutated gliomas that arise due to heritable or somatic defects in DNA repair have demonstrated clinically significant responses to immunotherapy by checkpoint blockade.^{49,50} A phase II clinical trial has recently been launched to test immune checkpoint inhibitor nivolumab in IDH-mutant glioma patients with and without hypermutation (NCT03718767). As optimal adjuvant management of LGG continues to be defined, future and ongoing studies should examine *MGMT* promoter methylation as a predictive biomarker to confirm its clinical utility for patient monitoring and treatment.

Supplementary Material

Supplementary data are available at *Neuro-Oncology* online.

Keywords

biomarker | glioma | hypermutation | MGMT | temozolomide

Funding

This work was supported by the National Institutes of Health (1F32CA239472–01 and 5T32CA151022–09 to R.M., R01CA169316 to J.F.C., and P50CA097257 to J.F.C. and S.M.C.). Additional support was provided by a gift from the Dabbiere family.

Data Availability

All relevant sample information, patient annotations, and data from BSAS, Infinium Array, exome and RNA sequencing are provided in [Supplementary Table 3](#) and [Supplementary Table 4](#). Previously published datasets are available at the European Genome-Phenome Archive EGAS00001000579 [refs ^{11,14,18}], EGAS00001001255 [ref ¹⁸], and EGAS00001001854 [ref ¹⁹]. New datasets are available at EGAS00001003956. Code is available on Github (radhikamathur/MGMT-Project/MGMT_Code.R).

Conflict of interest statement. No conflicts of interest to declare.

Acknowledgments

We thank the staff at the UCSF Brain Tumor Research Center Tissue Core for timely and significant contributions of key samples. We thank the Center for Advanced Technology at UCSF and the Targeted DNA Methylation & Mitochondrial Heteroplasmy Core at the University of Oklahoma Health Science Center for services in genomic sequencing and analysis.

Authorship statement. Experimental design: R.M., J.F.C.; implementation: R.M., Y.Z., M.R.G., C.H., M.Z., S.B. J.J.P, A.M.M.; data analysis and interpretation: R.M., Y.Z., M.R.G., M.Z., S.B., K.P., J.C., M.S.B., J.J.P, N.A.O., A.M.M., S.M.C., J.F.C; writing: R.M. with input and approval from all authors.

References

1. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *N Engl J Med*. 2015;372(26):2481–2498.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World health organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol*. 2016;131(6):803–820.
3. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. *Nat Rev Neurol*. 2019;15(7):405–417.

4. Oberheim Bush NA, Chang S. Treatment strategies for low-grade glioma in adults. *J Oncol Pract*. 2016;12(12):1235–1241.
5. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. *J Neurosurg*. 2011;115(5):948–965.
6. Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated hypermutation in gliomas. *Neuro Oncol*. 2018;20(10):1300–1309.
7. Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncol*. 2016;17(11):1521–1532.
8. Wahl M, Phillips JJ, Molinaro AM, et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. *Neuro Oncol*. 2017;19(2):242–251.
9. Bodell WJ, Gaikwad NW, Miller D, Berger MS. Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors. *Cancer Epidemiol Biomarkers Prev*. 2003;12(6):545–551.
10. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res*. 2006;66(8):3987–3991.
11. Johnson BE, Mazar T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science*. 2014;343(6167):189–193.
12. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. *Oncogene*. 2004;23(1):1–8.
13. Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). *Int J Oncol*. 2015;47(2):417–428.
14. van Thuijl HF, Mazar T, Johnson BE, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. *Acta Neuropathol*. 2015;129(4):597–607.
15. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*. 2008;455(7216):1061–1068.
16. Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. *Nat Genet*. 2016;48(7):768–776.
17. Jonsson P, Lin AL, Young RJ, et al. Genomic correlates of disease progression and treatment response in prospectively characterized Gliomas. *Clin Cancer Res*. 2019;25(18):5537–5547.
18. Mazar T, Pankov A, Johnson BE, et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. *Cancer Cell*. 2015;28(3):307–317.
19. Mazar T, Chesnelong C, Pankov A, et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. *Proc Natl Acad Sci U S A*. 2017;114(40):10743–10748.
20. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome Biol*. 2016;17:31.
21. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature*. 2013;500(7463):415–421.
22. Masser DR, Berg AS, Freeman WM. Focused, high accuracy 5-methylcytosine quantitation with base resolution by benchtop next-generation sequencing. *Epigenetics Chromatin*. 2013;6(1):33.
23. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics*. 2011;27(11):1571–1572.
24. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res*. 2017;45(4):e22.
25. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. *Acta Neuropathol*. 2012;124(4):547–560.
26. Bady P, Delorenzi M, Hegi ME. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. *J Mol Diagn*. 2016;18(3):350–361.
27. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923–930.
28. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
29. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics*. 2007;8(1):118–127.
30. Molinaro AM, Lostritto K, van der Laan M. partDSA: deletion/substitution/addition algorithm for partitioning the covariate space in prediction. *Bioinformatics*. 2010;26(10):1357–1363.
31. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc Natl Acad Sci U S A*. 2013;110(10):4009–4014.
32. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science*. 2014;344(6190):1396–1401.
33. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. *Cancer Res*. 1999;59(4):793–797.
34. Harris LC, Remack JS, Brent TP. Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. *Nucleic Acids Res*. 1994;22(22):4614–4619.
35. Qian XC, Brent TP. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. *Cancer Res*. 1997;57(17):3672–3677.
36. Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. *Neuro Oncol*. 2009;11(4):348–356.
37. Malley DS, Hamoudi RA, Kocalkowski S, Pearson DM, Collins VP, Ichimura K. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. *Acta Neuropathol*. 2011;121(5):651–661.
38. Khan A, Fornes O, Stigliani A, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Res*. 2018;46(D1):D260–D266.
39. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012; 489(7414), 57–74.
40. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med*. 2005;352(10):997–1003.
41. Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial. *JAMA Oncol*. 2018;4(10):1405–1409.
42. Brandes AA, Franceschi E, Tosoni A, et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. *Neuro Oncol*. 2010;12(3):283–288.
43. Suzuki T, Nakada M, Yoshida Y, et al. The correlation between promoter methylation status and the expression level of

- O6-methylguanine-DNA methyltransferase in recurrent glioma. *Jpn J Clin Oncol.* 2011;41(2):190–196.
44. Jung TY, Jung S, Moon KS, et al. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. *Oncol Rep.* 2010;23(5):1269–1276.
 45. Christmann M, Nagel G, Horn S, et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. *Int J Cancer.* 2010;127(9):2106–2118.
 46. Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. *Cancer Cell.* 2018;34(2):186–195.
 47. Natsume A, Wakabayashi T, Miyakita Y et al. Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas. *J Clin Oncol.* 2019;37(15_suppl):2004–2004.
 48. Daniel P, Sabri S, Chaddad A, et al. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. *Front Oncol.* 2019;9:41.
 49. Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. *J Clin Oncol.* 2016;34(19):2206–2211.
 50. Johanns TM, Miller CA, Dorward IG, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. *Cancer Discov.* 2016;6(11):1230–1236.